

Hadasit Newsletter / August 2018

INNOVATION SPOTLIGHT

Message from the CEO, Dr. Tamar Raz


INNOVATION UPDATES

With promising new research underway, the first half of 2018 has been one of growth and advancement. Since the beginning of the year we have initiated 21 new projects and signed more than 20 license-related agreements. Here at Hadasit we remain leaders in bringing innovation from the lab to the marketplace and transforming research into commercial technologies.

Last month, the Israel Innovation Authority (IIA) announced the winners of the last round of Kamin grants (for promoting applied research in academia). We are proud to share that the IIA approved six of our seven projects submitted for funding. With an 85% approval success rate, Hadasit ranks first in grants awarded by the IIA and will receive NIS 2.1 million in Kamin grants to advance the research of **Prof. Eithan Galun, Prof. Yoav Mintz, Prof. Rachel Katz-Brull, Prof. Danielle Melloul, Dr. Sharon Merims, and Prof. Gideon Zamir.**

Hadasit also continues to actively scout for new ideas at Hadassah, encouraging physicians and inventors to apply for new patents and facilitating this process. We are happy to introduce the top performing departments at Hadassah, led by the Departments of Internal Medicine which holds the most patents of any department - 65 applications and granted patents. The departments of Oncology, Obstetrics & Gynecology, follow closely behind, leading in their individual fields. The top six departments comprise more than 60% of our patent portfolio. We hope to see more departments at Hadassah join this "club" of top performers that hold 10 or more patents per department.

I hope you'll enjoy reading this third edition of our newsletter and learning about the exciting work we are doing here at Hadasit as we aim to improve healthcare, patient care, and the medical industry. ■



Hadasit Newsletter / August 2018

INNOVATION SPOTLIGHT (p.2)



Confocal image of human T cells activated with anti-CD3, with SLAMF6 (yellow) clustering at sites of cell-cell contact

Driving Innovation in the Field of Immune-Oncology


Ferring Holding (FHL, the Israel affiliate of Ferring Pharmaceuticals SA) will fund oncologist **Prof. Michal Lotem**'s research on innovative and groundbreaking technology in the field of immune-oncology. As part of the collaboration, FHL will harness its team's extensive expertise in biologics expression and scaleup. We hope that the combination of Hadassah research and the drug development and manufacturing expertise of FHL will bring Prof. Lotem's technology to cancer patients around the world.

Ferring Pharmaceuticals SA is a global, research-driven, specialty biopharmaceutical company that is a leader in reproductive medicine and women's health and in specialty areas within gastroenterology and urology. Hadasit and FHL are joining forces to identify additional projects for joint development and funding.



Interested in applying for the funding by FHL?

Contact Dr. Tal Almog, VP of Business Development, talal@hadassah.org.il ■



Blood Test for Early Cancer Detection

The California-based company Grail has entered into strategic partnership with a team of HUJI researchers headed by **Prof. Yuval Dor of the Faculty of Medicine and Prof. Benjamin Glaser of Hadassah**. Grail was founded in 2016 after raising more than \$1.5 billion from investors including Bill Gates, Johnson & Johnson, and Bezos Expeditions, the personal investment arm of Jeff Bezos.

Using a process called DNA methylation, the Israeli team is creating a method to determine the tissue origin of DNA circulating in the blood (ctDNA). When methyl groups are added to a molecule of DNA they can alter the way genes are expressed, without altering the genetic code itself. These epigenetic "identity markers" are typical to each cell type. As part of the program sponsored by Grail, Israeli researchers will collaborate with the company to generate methylation data from multiple cell types. The data will then be used to create a method for interpreting the source of blood-based signals. Most of the research will be conducted in Jerusalem in collaboration with Grail, and any future technological applications will belong to Yissum, Hadasit and Grail. ■

Hadasit Newsletter / August 2018

INNOVATION SPOTLIGHT (p.3)



Hadassah BioDesign Project Raises NIS 3 Million

After first meeting at the BioDesign course of Hadassah and the Hebrew University of Jerusalem, cardiologist **Dr. Ran Eliaz** and surgeon **Dr. Yonathan Demma**, together with Mr. Ziv Menshes (MBA) and Mr. Or Hazan (LLB), have founded CardioVia- a NIS 3 million company established under the NGT3 VC incubator.

CardioVia will develop a device capable of entering the tissue surrounding the heart, the pericardium, without a needle, thereby enhancing the safety of the procedure while providing access for future pacing and ablation solutions on the heart surface. The potential market estimation for the device is \$0.5 billion per year in the U.S. alone.

BioDesign is a two-semester academic course at HUJI, mentoring cohorts comprised of Hadassah clinicians and HUJI bioengineering, business and law students. The program was established by **Prof. Chaim Lotan** and is managed by **Prof. Yoav Mintz**.



Interested in applying for the upcoming BioDesign October class?

Contact Ariel Rabin, VP of Business Development, arielr@hadassah.org.il ■



Ariel Rabin

VP of Business Development,
Medical Devices

Hadasit Collaboration with Azrieli Yields 6 New Medical Device Projects

Hadassah clinicians met with top engineers from the Azrieli College of Engineering to discuss their unmet needs in the areas of surgery, oncology, ICU, orthopedics and dentistry. Together they came up with innovative ideas for technologies and devices that would facilitate targeted, more effective treatment for patients.

There are now six new projects under development. Among them, **Prof. Yoav Mintz** (surgery) is working with Azrieli's **Dr. Tali Tavor Re'em** on a new anti-adhesive coating method for hernia mesh. Additionally, oncologist **Dr. Yakir Rotenberg** and Azrieli's **Dr. Haytem Kasem** are working on extending the intravenous functional duration of PIV (venflons).

"Clinicians and engineers is the right combination in medical devices and digital health projects," says Ariel Rabin, Hadasit VP of Business Development. "Over my almost four years at Hadasit, 13 health tech projects were licensed, establishing 10 existing companies which raised over \$15M (USD) to date. Other portfolio projects generated around \$2M in research funding and commercialization revenues."



Do you have a new idea?

Are looking for a development partner or a way to jumpstart your project?
Contact Ariel Rabin, VP of Business Development, arielr@hadassah.org.il ■